Reactivation of Latent Tuberculosis After Treatment With Biologic Therapy

Tuberculosis reactivation during novel, biologic therapy

Tuberculosis reactivation during novel, biologic therapy Cristina Popescu, Violeta Molagic, Cătălin Tilişcan, Ruxandra Moroti, Adriana Hristea, Mihaela Rădulescu, Raluca Mihăilescu, Daniela Munteanu, Iulia Niculescu, Raluca Năstase, Raluca Dulama, Alina Lobodan, Raluca Hrişcă, Raluca Jipa, Anca-Ruxandra Negru, Irina Lăpădat, Roxana Petre, Mircea Chiotan, Cornel Camburu, Viorica Poghirc, Raluca ...

Reactivation of Latent Tuberculosis Infection

Risk of tuberculosis reactivation with rituximab therapy

BACKGROUND Tuberculosis (TB) is one of the world's deadliest diseases, and one-third of the world's population is infected with it. The link between antitumor necrosis factor therapy and reactivation of latent TB is well recognized. However, only limited studies have evaluated the risk of TB with rituximab, a B-cell-targeting therapeutic agent used recently for rheumatological diseases, primari...

Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection.

Since Robert Koch described the cause of tuberculosis in 1882, the natural history of the disease after primary infection has been subject to debate. Only approximately 10% of infected individuals develop active disease, which may appear years to decades after infection. Late onset has been attributed to the endogenous reactivation of dormant bacteria. However, this has not been documented by m...

Reactivation of latent tuberculosis: variations on the Cornell murine model.

Mycobacterium tuberculosis causes active tuberculosis in only a small percentage of infected persons. In most cases, the infection is clinically latent, although immunosuppression can cause reactivation of a latent M. tuberculosis infection. Surprisingly little is known about the biology of the bacterium or the host during latency, and experimental studies on latent tuberculosis suffer from a l...